TRACON Pharmaceuticals, Inc. (TCON)

TRACON Pharmaceuticals, Inc. (TCON) — VMCI valuation read

TRACON Pharmaceuticals, Inc. sits at VMCI 57/100, with the Healthcare sector median at 50. That 7-point spread is the first thing to note on TCON: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on TCON are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on TCON: TCON trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp. The Risk read: net debt to EBITDA of 2.9x is the rate-sensitivity line to watch, anchoring the bear scenario on a measurable balance-sheet metric.

TCON fell 0.8% over the trailing 7 days, with a -14.4% read on a 30-day basis.